1. Home
  2. Directory
  3. New York
  4. New York New York
  5. Radiology
  6. NPI Profile
  7. Prescriptions 1376868554

DR. HIMANSHU NAGAR M.D.
Prescription History 1376868554
Radiology - Radiation Oncology in New York, NY


Quality Rating: 90.38 out of 100 score

NPI Status: Active since March 31, 2010

Contact Information

1275 YORK AVE
NEW YORK, NY
ZIP 10065
Phone: (212) 639-2000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. HIMANSHU NAGAR M.D., an active Radiation Oncology specialist practicing in New York, NY. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 170 documented patient claims. Among these therapy options, the most frequently utilized medication is Tamsulosin Hcl, which accounts for 109 claims alone.

Medication Index

M
O
S
T
No matching medications currently found on file.

Methylprednisolone

Generic Formulation: MethylprednisoloneSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 72
NY State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.4
Peer Average Days Supply271
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.5% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $139.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.66

State Avg Cost Per Claim

$11.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A PREDNISOLONE derivative with similar anti-inflammatory action.

Therapeutic Applications

Methylprednisolone is used to treat conditions such as arthritis, blood disorders, severe allergic reactions, certain cancers, eye conditions, skin/kidney/intestinal/lung diseases, and immune system disorders. It decreases your immune system's response to various diseases to reduce symptoms such as swelling, pain, and allergic-type reactions. This medication is a corticosteroid hormone. Methylprednisolone may also be used with other medications in hormone disorders.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 32.0
Days Supply 960
NY State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills83.7
Peer Average Days Supply2,418
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.3% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,361.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$768.10

State Avg Cost Per Claim

$638.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Orgovyx

Generic Formulation: RelugolixSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 358
NY State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills41.9
Peer Average Days Supply1,250
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.7% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,820.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,568.36

State Avg Cost Per Claim

$2,629.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Relugolix is used to treat prostate cancer in men. It is not a cure. Most types of prostate cancer need the male hormone testosterone to grow and spread. Relugolix works by reducing the amount of testosterone that the body makes. This helps slow or stop the growth of cancer cells.

Silodosin

Generic Formulation: SilodosinSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 33.0
Days Supply 990
NY State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills78.4
Peer Average Days Supply2,325
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.5% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,797.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$105.76

State Avg Cost Per Claim

$131.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Silodosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Silodosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Tamsulosin Hcl

Generic Formulation: Tamsulosin HclSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 109
30-Day Fills 242.0
Days Supply 7,213
NY State Average Benchmarks
Peer Average Claims92.0
Peer Average 30-Day Fills183.8
Peer Average Days Supply5,404
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,836.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.02

State Avg Cost Per Claim

$19.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. HIMANSHU NAGAR M.D. provides transparency into local medical care patterns within New York, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Radiation Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.